CardioInsight’s Unique Electrical Activation Mapping Technology Offers Non-invasive Imaging of Heart’s Electrical Activity
CardioInsight Technologies, Inc., a new Cleveland bioscience start-up company, will commercialize a unique technology known as electrocardiographic imaging that was developed by Case Western Reserve University, in association with University Hospitals of Cleveland. The partners announced the launch of the new high-tech business today.
This collaborative enterprise recently closed an initial round of financing. CardioInsight is funded by Draper Triangle Ventures, JumpStart Inc. and Case Technology Ventures. The investment will be used to construct an advanced prototype of the company's imaging technology device, to conduct additional clinical studies and to advance the company's business plan.
"We're pleased at the validation of our technology as represented by this investment," said Warren
Goldenberg, CardioInsight's CEO. "The funding will allow us to conduct additional clinical trials and to map out a strategy for regulatory approval and market entry."
"The CardioInsight technology has the potential to enable physicians to diagnose and treat arrhythmias and other heart problems related to electrical function without performing an invasive procedure," said Jay Katarincic, a managing director at Draper Triangle. "The current gold standard for gathering this type of data is an electrophysiology study, which is invasive, expensive, time consuming and risky. CardioInsight's approach offers a more effective option and addresses a potentially significant market."
CardioInsight represents an extensive collaboration among company co-founders Charu Ramanathan and Ping Jia, who both earned doctorates in biomedical engineering at Case Western Reserve University, and several Greater Cleveland research institutions. This new technology was developed at Case in the laboratory of Yoram Rudy, PhD, principal inventor. Initial human trials of the device were conducted at University Hospitals of Cleveland. Case and JumpStart, a venture development organization that assists high-growth startups within the region, collaborated to refine the company’s business plan, recruit Warren Goldenberg as interim CEO and introduce Draper Triangle to the company. BioEnterprise, the region's bioscience business formation, recruitment, and acceleration initiative, participated in assessing the technology and its potential market.
About CardioInsight Technologies, Inc.
CardioInsight is being formed to commercialize electrocardiographic imaging technology developed at Case. The CardioInsight Technology non-invasively images electrical activity on the surface of the heart. Patented algorithms are used to combine body surface electrical data and chest CT scans to non-invasively generate maps of the electrical activity of the heart during each heart beat. Proof of concept has been demonstrated in animal studies and preliminary human studies. The Company has a strong clinical advisory board, including Dr. Albert Waldo (UHHS), Dr. Jayakumar Sahadevan (UHHS and Cleveland VA Medical Center), Dr. Yoram Rudy (Washington University, St. Louis), Dr. William Stevenson (Brigham and Women's, Boston), and Drs. David Wilber and Niraj Varma (Loyola, Chicago).
About Draper Triangle Ventures
Draper Triangle Ventures is the Midwestern-based fund of Draper Fisher Jurvetson (DFJ), the leader in seed and early-stage venture capital. Draper Triangle is a premier source of funding for high-technology start-up companies in the Pennsylvania and Ohio region.
About JumpStart Inc.
JumpStart (www.jumpstartinc.org) accelerates the growth of early-stage businesses and ideas into venture-ready companies by delivering vital, focused resources to entrepreneurs in Northeast Ohio. JumpStart identifies and invests in early-stage companies that have strong potential in the marketplace, solid prospects for high growth, and are likely to qualify for later-stage funding. Beyond investing, the JumpStart team provides a continuum of business development services to its client companies to help ensure their success.
About Case Technology Ventures
Case Technology Ventures (CTV) is Case Western Reserve University’s five million dollar technology validation fund. CTV focuses on creating new companies for the Northeast Ohio region by providing capital to pre-seed stage companies based on intellectual property developed at Case and its affiliate institutions. Financial support comes from Case Western Reserve University and the State of Ohio’s Third Frontier Project.
BioEnterprise is a business formation, recruitment and acceleration initiative designed to grow health care companies and commercialize bioscience technologies. Based in Cleveland, BioEnterprise’s founders and partners are The Cleveland Clinic, University Hospitals Health System, Case Western Reserve University and Summa Health System. Companies include emerging medical device, biotechnology and health care services firms.